To determine the role of carnitine supplementation in premature infants on apnea of prematurity, length of ventilation and duration of hospital stay.
RATIONALE AND BACKGROUND
Apnea of prematurity is a common problem in preterm infants in the neonatal intensive care setting (NICU), often delaying their discharge home or transfer to a stepdown unit. Episodes of apnea are generally defined as periods during which there is cessation of neonatal breathing activity for greater than 20 seconds or those of less than 20 seconds with associated bradycardia, pallor and/or cyanosis. 1 There are reports that suggest that apneic episodes, particularly 20 seconds or more in duration, are correlated with adverse neurological development. 2 At present, methylxanthines (aminophylline, theophylline and caffeine) are the mainstays of treatment for this condition, exerting their effect primarily by stimulation of the respiratory center in the brain. However, there are concerns with the short-term and the long-term safety of these compounds. Besides, the commonly seen side effects of feeding intolerance and tachycardia, these drugs have also been implicated in serious adverse effects such as cardiac arrhythmias and exacerbation of ischemic brain injury. [3] [4] [5] Doxapram is another respiratory stimulant that is sometimes used when methylxanthine treatment has failed. However, this drug has to be administered intravenously and is also associated with side effects such as seizures, liver dysfunction and gastrointestinal irritation that have limited its use. 6 In the NICU, preterm infants are continuously monitored for apneic episodes by heart rate, respiratory rate and oxygen saturation. These episodes may range in severity from those that resolve spontaneously, those that require stimulation of the infant or those that require artificial ventilation. However, with time the apneic episodes become less severe, and the respiratory stimulants can be discontinued while continuing to monitor the infant. Monitoring of infants is usually discontinued when they have remained apnea free for 3 to 10 days, the exact duration varying between individual NICUs. 7, 8 Carnitine, a quaternary amine synthesized from the amino acid lysine, is essential for the transport of fatty acids across mitochondria membranes for beta-oxidation metabolism and ketone generation. 9 Deficiency of carnitine leads to a decrease in long-chain fatty acids that are available for beta-oxidation, resulting in a decrease in energy production at the muscular level. Carnitine deficiency has been shown to be associated with generalized hypotonia, respiratory insufficiency and respiratory failure in neonates 10, 11 and in adults. 12 Carnitine is stored in fetal tissues in increasing amounts over the latter part of gestation. Premature infants are at increased risk of tissue carnitine deficiency because of the immaturity of the carnitine biosynthetic pathways. In addition, reduced placental transfer and reduced intakes from breast milk or conventional parenteral nutrition solutions also contribute to carnitine deficiency in this population.
Treatment with carnitine has shown benefit in the respiratory status of ventilator-dependent adults, as well as stabilization of respiratory parameters and increased physical performance in adult patients with chronic respiratory insufficiency. [15] [16] [17] Iafolla et al. 18 in a case series, showed a dramatic decrease in episodes of apnea and periodic breathing in infants with carnitine deficiency following 48 hours of treatment with 100 mg/kg/day of oral carnitine. There have been no serious side effects reported with carnitine supplementation in preterm infants. At present, it is unlikely that carnitine would be used in place of xanthines for the primary treatment of apnea of prematurity when its effects have not been conclusively proven in large trials. However, it may have a place in the prevention or in the secondary treatment of apneic episodes. To date, there has been no systematic review to evaluate the role of carnitine supplementation for apnea of prematurity.
SEARCH STRATEGY
Two reviewers (MK and NS) performed a literature search independently to identify prospective randomized controlled trials in which the subjects were premature infants either with or at risk of apnea of prematurity in which a primary or secondary outcome variable was apnea frequency. The following databases were searched:
Medline ( The following terms were used in the searches (all headings): (Carnitine or L-carnitine or carnitor or carnitin*) AND (apnea or apnoea or ''apnea or prematurity'' or ''apnoea of prematurity'' or respiratory insufficiency or respiratory failure or ventilation or ventilator or respirator) AND (newborn or infant).
We conducted a hand search of the Journal of Perinatology Contacts were made with drug manufacturers, authors of previously published works and subject experts for any unpublished material and for ongoing trials. Searches were not restricted by language.
Decisions to include studies for the review were based on predetermined criteria (Table 1) . Two reviewers (MK and NS) separately analyzed the abstracts of all the identified studies and their results were compared (k 0.76, SE 0.122). Disagreements were resolved by discussion following a detailed review of the methods section of the individual studies.
Methodological quality was assessed using the criteria described in 'Effective care of the newborn infant'. 19 Two reviewers independently assessed the methodological quality of the included studies and differences were resolved by discussion. Outcome information on apnea and significant apnea (apnea episodes requiring any form of intervention, e.g., increased oxygen delivery, tactile stimulation or bag and mask ventilation), length of ventilation and duration of hospital stay was recorded on a standardized data extraction form. Mortality and other adverse events were also recorded. Where data were incomplete corresponding authors were contacted for further information. Authors of the included studies were electronically mailed the data extraction form for their approval of information provided in their respective studies and for additional information required for the analysis.
A priori decisions of including only random/quasirandom trials for summary estimate, to conduct subgroup analysis among patients not receiving methylxanthines and a sensitivity analysis including only double-blinded randomized trials were made at the protocol stage.
Data were synthesized using Rev Man 4.2 software. Relative risk (RR) for dichotomous data and weighted mean difference (WMD) for continuous data were chosen for summary effect size estimation using a random effect model.
RESULTS

Description of the Studies
Three trials evaluating the effect of carnitine supplementation on apnea of prematurity were identified. One treatment trial, 20 which was published as an abstract, was excluded after receiving communication from one of its authors who stated that the results of the study were found to be incorrect and thus were not submitted for full text publication. Both the included studies 21, 22 enrolled patients within 2 to 4 days following birth and were prevention trials. Both studies used carnitine supplementation in the parenteral nutrition, followed by a change to oral supplementation when the infants were on predominantly enteral feeding. Supplementation was continued until 34 to 36 weeks of postconception age. Details of the included studies are presented in the table of the included studies (Table 2) . Both studies had methylxanthines as a cointervention for most of the included subjects. O'Donnell et al. also used doxapram for some of their subjects. Whitfield et al. showed low carnitine levels at baseline in both the treatment and placebo groups, followed by a significantly higher level in the supplemented group at 4 and 8 weeks from baseline. However, the carnitine levels in the placebo group were also noted to rise into the normal range during the course of the study (postulated to be obtained from exogenous sources like breast milk or preterm formula and/or from endogenous synthesis). O'Donnell's study measured carnitine levels only once at 14 days of life. This study showed significantly higher levels in the supplemented group (median 195.3 mmol/l; range 71.7 to 343.6 mmol/l) whereas the levels in the placebo group were below normal (median 15.5 mmol/l; range 7.06 to 30.5 mmol/l).
Outcomes Measured
Apnea Both studies reported nurse-recorded frequency of apneic episodes averaged over 12 hours time (Table 3 ). In O'Donnell's study there was no difference between the groups for frequency of apneic episodes at 10 days, 30 weeks and 34 weeks post conception age (PCA). However, there was a trend towards a beneficial effect with supplementation at 34 weeks PCA (Mean difference À1.5, 95% CI À3.1 to 0.1 episodes, p-value 0.07). Whitfield et al. calculated nurse-recorded apnea frequency as average of episodes recorded over the duration of NICU stay and found no difference between the groups. The outcomes were not combined for a summary estimate.
Both studies also recorded apneic episodes with the help of continuous objective recording devices. O'Donnell et al. recorded apnea frequency by analyses of the tracing of cardiorespirograms 
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Carnitine Supplementation in Apnea of Prematurity (CRG), and combined use of the respiratory impedance method and nasal thermistor probe. Whitfield's study did not employ the use of the nasal thermistor probe. Neither of the studies found any difference between the supplemented and the placebo group for frequency of apneic events at various stages ( Table 4 ). The outcomes were not combined for a summary estimate.
Duration of ventilation
There was a slight decrease in IPPV duration in the supplemented group; however, the difference was not significant (mean difference À3.24 days, 95%CI À8.39 to 1.92 days, p-value 0.22) (Figure 1) . Similarly, there was no difference among the groups for CPAP duration (data not provided).
Length of hospital stay There was a marginal decrease in the number of days of hospitalization; however, the difference was not significant (mean difference À5.4 days, 95% CI À15.53 to 4.72 days, p-value 0.30) (Figure 2 ).
Adverse Effects
There was one death in the placebo group in O'Donnell's study and four deaths (two in each arm) in Whitfield's study. O'Donnell et al. also reported data on other neonatal morbidities, for example, intraventricular hemorrhage, necrotizing enterocolitis (NEC) or NEC requiring surgical intervention, retinopathy of prematurity (ROP) or ROP requiring surgical intervention. There was no difference in any of these outcomes between the study groups.
DISCUSSION
We did not find any difference in apnea of prematurity as recorded by bedside nurses or with the use of continuous objective recording devices when preterm infants were supplemented with carnitine orally or in their TPN solutions. Similarly, there were no significant differences among the groups for the duration of initial IPPV use and the hospital stay.
The results of nurse-recorded apnea were not combined for a summary estimate as this outcome was evaluated differently in the two studies. Whitfield et al. calculated nurse recorded apnea frequency as an average of episodes recorded over the entire duration of the NICU stay, whereas O'Donnell et al. reported the results of this outcome at multiple time points during the period the infants were hospitalized in the NICU.
Similarly, the results of continuous objective recordings of apnea were not combined for a summary estimate because the included studies employed different methods for recording the events. Whitfield et al. did not make use of a nasal thermistor probe in their set up. They would have, therefore, likely missed recording most of the obstructive apnea episodes and a proportion of mixed apnea episodes. In fact this is evident from reviewing the results of the individual studies; 5 to 10 times higher apnea events were recorded in O'Donnell's study. In addition, there was a large attrition rate for continuous objective recording of the apnea in Whitfield's study. The authors attributed this loss of data to lack of availability of recording machines or technicians.
This lack of effect could be related to many factors. Carnitine levels were seen to rise with time into the normal range even in the placebo group in Whitfield's study. This elevation of carnitine levels was postulated as resulting from exogenous sources like breast milk or preterm formula and/or from endogenous synthesis. The authors of this study had calculated nurse-recorded apnea frequency as an average of episodes recorded over the entire duration of the NICU stay. It is possible that there was some effect from carnitine at the onset, which was later lost due to the contamination effect. However, O'Donnell et al. could also not document benefit as early as 10 days postsupplementation when the placebo group had plasma carnitine levels below normal. O'Donnell et al. also did not measure plasma carnitine concentration later than the 14th day of life.
Another reason for this lack of effect could be due to the cointervention of methylxanthines, which were used in most patients in both studies. O'Donnell et al. also used doxapram as a respiratory stimulant in about one-third of their patients. Therefore, these studies actually examined the effect of carnitine in the presence of conventional respiratory stimulants. We anticipated this problem and had therefore decided to conduct a subgroup analysis among patients not receiving these drugs. However, this was not possible due to the small number of patients available for subgroup analysis. With the current practice of liberal use of methylxanthines, it seems unlikely that this clinical question can be answered at this time.
It is possible that carnitine has an effect on the quality of the apneic episodes, which may manifest as a decrease in the number of significant apnea episodes. Although, both the included studies used a classification for severity of apnea, neither of the studies provided data for significant apnea requiring interventions, such as physical stimulation by a bedside nurse or bag and mask ventilation.
It seems that an optimum sample size to evaluate comprehensively for apnea of prematurity was not achieved. The larger of the two studies by Whitfield et al. documented that the original sample size calculation was made with the assumption of a 70% incidence of apnea. In fact, the actual incidence was only 28%. It is possible that a larger study may have detected a significant difference between the groups.
We did not apply any formal tests for publication bias. Construction of a funnel plot was not possible with such a limited number of studies. However, it appears unlikely that we would have missed an important study as our search strategy was broad. Two reviewers had conducted an independent search using seven electronic databases and exhaustive efforts were made to identify unpublished studies.
IMPLICATIONS FOR FUTURE RESEARCH
Despite the plausible rationale, this systemic review does not support the use of routine carnitine supplementation for apnea of Figure 2 . Duration of hospital stay before discharge home (in days).
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Carnitine Supplementation in Apnea of Prematurity prematurity. However, the role of carnitine supplementation without the cointervention of respiratory stimulants was not possible to evaluate due to the lack of an adequate number of patients for subgroup analysis.
There are concerns about adverse effects from the use of various respiratory stimulants. Currently, a large randomized trial examining the effects of caffeine on long-term neurodevelopmental outcomes is underway (B. Schmidt, Principal investigator, caffeine for apnea of prematurity (CAP Trial), multi-center trial, personal communication). If the results of this study demonstrate deleterious effects from these drugs, there may be a case in the future for conducting a trial of carnitine supplementation as a primary agent for apnea of prematurity without the cointervention of methylxanthines.
Future trials should also examine other clinically relevant outcome measures such as the achievement of a 5 to 7-day apnea free interval, proportion of patients with continuing apneic episodes or need for ventilatory support (CPAP or IPPV) at various time points.
